ClinicalTrials.gg
Not yet recruitingNCT06506227Updated Jul 17, 2024

Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype

An interventional study of Low risk experimental group and Medium risk experimental group in Adolescent Idiopathic Scoliosis, sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University. Not yet recruiting at 1 site in China. Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Non-randomized
Ages
10 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Scoliosis with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Scoliosis · China.

Planned enrollment
Largest of 37
2,000 · median 100
Started
2024
with 5 others
No phase
31 of 55
14 open now
Primary completion
2026-12
later than 12 of 25 live
Registered
38th of 55
by date
Lead sponsor
7 of 55
The First Affiliated Hospital of Zhejiang Chinese Medical University

Among the 55 studies in Scoliosis with a site in China, this one has the largest planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2024, is one of 31 with no phase, reaches primary completion later than 12 of the 25 other live ones, and was the 38th registered.

Scoliosis

660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.

Browse Scoliosis studies →

Open to participants now

22 of the 55 studies in Scoliosis with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.

This study: 10 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Scoliosis with a site in China, or all of them as a file.
02

Study summary

Mining AIS biomarkers, elucidating the new mechanism of AIS pathogenicity, constructing risk prediction models, optimizing AIS precise diagnosis and treatment techniques, formulating precise diagnosis and treatment protocols and technical specifications for AIS combined with Chinese and Western medicine with independent intellectual property rights, and realizing the full coverage of Zhejiang Province by the end of 2026, so as to form the "Zhejiang experience" of AIS diagnosis and treatment.

Read the detailed description

Currently, there are problems of high genetic and phenotypic heterogeneity in AIS research, lack of in-depth epigenetic studies, and lack of clarity in pathogenic mechanisms. This project proposes to use EWAS technology, combined with a hybrid model of multidimensional and multimodal data fusion, to realize a multi-omics joint analysis, to clarify the amount of synergistic effects between multi-omics risk factors and AIS, to draw a map of modifiable risk factors, to clarify AIS biomarkers, and to reveal AIS To clarify the biomarkers of AIS and reveal the pathogenic mechanism of AIS. Currently, the clinical diagnosis and treatment of AIS is highly subjective and lacks objective and accurate risk prediction, which makes it easy to make wrong clinical decisions, resulting in insufficient, delayed or excessive treatment, missing the optimal time for treatment, and poor clinical efficacy. This project intends to establish a multi-dimensional and multi-modal dynamic database, use the unified model construction technology, combined with the sample imbalance model, to construct a unified and accurate prediction model for AIS, to perform clinical typing and risk stratification for AIS, to establish individualized and accurate diagnostic and treatment protocols for AIS, to improve the efficacy of AIS, to obtain high-quality clinical evidence, and to formulate industry-recognized clinical prevention and treatment standards, norms, and guidelines. Through mining AIS biomarkers, elucidating new mechanisms of AIS pathogenicity, constructing risk prediction models, optimizing AIS precision diagnosis and treatment techniques, and formulating precise diagnosis and treatment protocols and technical specifications for AIS combining Chinese and Western medicine with independent intellectual property rights, the project will achieve full coverage of Zhejiang Province by the end of 2026, forming the "Zhejiang experience" in AIS diagnosis and treatment. Zhejiang experience" will be formed in AIS diagnosis and treatment. The promotion of the results can realize the precision of AIS diagnosis and treatment, improve the efficacy of AIS treatment, reduce the incidence of severe scoliosis, reduce medical expenditure by billions of dollars, and alleviate the economic burden on families and society.

03

Conditions studied

  • Adolescent Idiopathic Scoliosis

Browse trials for

04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with AIS;② Sex is not limited, age 10-18 years old; ③ Those who sign the and can cooperate with follow-up visits; ④ Those who can cooperate with X-ray, chemical test, genetic test and other examination and evaluation for the measurement of relevant indexes.

Exclusion criteria

Exclusion Criteria:

  • Subjects with spine-related diseases such as Marfan's syndrome;

    • Subjects with previous ankylosing spondylitis, spinal neurofibroma, spinal tuberculosis, spinal trauma and other spine-related diseases;

      • Subjects with combined serious medical diseases and psychiatric patients;

        • Those with score > 2, which may have an impact on the study results;

          • Those who are affected by external factors such as economy, individualized differences, etc., so that they cannot complete the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    according to the order of their visits then were assigned numbers

    The patients were assigned numbers according to the order of their visits, and after obtaining informed consent, they were divided into a treatment group and a control group to conduct a prospective cohort study.

    Behavioral: Low risk experimental group · Behavioral: Medium risk experimental group · Genetic: High risk experimental group · Behavioral: Control group COBB 10-20° · Behavioral: Control group COBB 20-45° · Behavioral: Control group COBB >45° · Other: Experimental group (AIS group) · Other: Control group (healthy control) · Other: Controlled follow-up before and after AIS

  • Experimental
    According to the order of their visits to the clinic, given the appropriate number,

    According to the order of their visits to the clinic, given the appropriate number, divided into the test group and the control group, in strict accordance with the results of the group, the appropriate treatment and observation of the group, the teams of personnel and the implementation of clinical treatment should not be the same person.

    Behavioral: Low risk experimental group · Behavioral: Medium risk experimental group · Genetic: High risk experimental group · Behavioral: Control group COBB 10-20° · Behavioral: Control group COBB 20-45° · Behavioral: Control group COBB >45° · Other: Experimental group (AIS group) · Other: Control group (healthy control) · Other: Controlled follow-up before and after AIS

Interventions

  • BehavioralLow risk experimental group

    Guiding + Manipulation + Traditional Chinese Medicine

  • BehavioralMedium risk experimental group

    Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces

  • GeneticHigh risk experimental group

    Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation

  • BehavioralControl group COBB 10-20°

    Specific Exercise Therapy

  • BehavioralControl group COBB 20-45°

    Orthopedic Braces + Specific Exercise Therapy

  • BehavioralControl group COBB >45°

    Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery

  • OtherExperimental group (AIS group)

    Molecular marker exploration and validation

  • OtherControl group (healthy control)

    Molecular marker exploration and validation

  • OtherControlled follow-up before and after AIS

    Construction and validation of AIS risk prediction model completed

06

What researchers measure

Primary outcomes

  1. Cobb Angle

    Cobb's angle is an angle used to measure the severity of scoliosis by measuring the angle of lateral curvature to assess the degree of scoliosis.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  2. Trunk Rotation Degree -Angle of Trunk Rotation

    The patient stood with feet shoulder-width apart and bent forward with hands to palms, and the maximum degree of spinal razorback was measured with the Scoliometer Scoliosis Screening Scale.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  3. Coronal Balance

    A plumb line is usually used to determine coronal plane balance. In the coronal plane of a normal spine, a plumb line leading from the center of the C7 vertebra will pass through the center of the sacrum or within 1 cm to the left and right of the S1 spinous process.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  4. Sagittal Balance

    Sagittal Balanced descriptions in the sagittal plane are an important way to assess scoliosis and its impact on body structure and function.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  5. Frontal Convexity Of the Spine Angle

    Your doctor will ask you to stand or sit down and then take x-ray pictures of your spine from the side. These pictures show the curve and curvature of the spine, from which the doctor can assess the condition of the lordosis.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  6. Offside Convexity Of the Spine Angle

    Your doctor will ask you to stand or sit down and then take x-ray pictures of your spine from the side. These pictures clearly show the curve and curvature of the spine, and the doctor can use these images to evaluate the condition of the kyphosis.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  7. Electromyographic (AEMG) indicators

    The obtained surface EMG signal data were input into MegaWin 2.3 signal processing software to extract and analyze linear metrics (mean frequency, median frequency, muscle activity intensity, etc.), and nonlinear metrics (multi-scale sample entropy, fractal dimension, coherence, etc.)

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  8. Electroencephalographic (EEG) Index

    Matlab based software and its toolkit EEGLAB were used to preprocess the data and get clean EEG signal. The effective number of channels acquired in this study was 18 leads. Fifteen 2s segments (i.e., 45s of data) were randomly selected for each subject to obtain δ (1-4Hz), θ (4-8Hz), α (8-13Hz), and β (13-30Hz), and the functional connectivity of the different bands was calculated separately.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  9. Postural Posture Assessment

    Measurements of trunk offset angle, pelvic tilt angle, thoracic lordosis angle, lumbar lordosis angle, the sum of the maximum angle of vertebral body left-right rotation, the sum of the maximum left-right deviation of the trunk, and the angle of primary bending and lateral curvature can be obtained after completion of the filming.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  10. Balance Function

    Subjects remained stationary with eyes open for 30 seconds, and four parameters of COP were recorded: area of COP oscillation, mean oscillation velocity in the anteroposterior (AP) and medial-lateral (ML) directions, and length of movement.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  11. Questionnaire on Spinal Health of Children and Adolescents

    The Spine Health Questionnaire for Children and Adolescents is designed to understand and assess the spine health status and related behaviors of this age group in their daily lives.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  12. Skeletal maturity (Risser's sign)

    Doctors determine a child's bone age based on the closest standard x-ray image in the atlas to how the child's bones appear on the x-ray.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  13. Types of scoliosis

    Although scoliosis presents all lateral curvature and vertebral rotation in the spinal phase, we can categorize it into different types based on the number of degrees of scoliosis when the degree of scoliosis is greater than ten degrees in the online screen slice mountain.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  14. Sagittal plane axial distance (SVA)

    Sagittal plane axial distance (SVA) is one of the most important indicators of spinal and body postural balance, especially when assessing anterior-posterior spinal balance. It is usually measured by imaging (e.g., X-rays or MRI) and is used to quantify the anterior-posterior positional differences between the head and a pelvis.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  15. Muscle and bone ultrasound

    Morphological characteristics of the paravertebral muscles were extracted by ultrasonography of the morphology and elasticity of the paravertebral muscles of the enrolled patients.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  16. Number of participants with Chemical testing

    Subjects were obtained for routine blood, urine, biochemistry, thyroid function, sex hormones, allergens, growth hormone, leptin, estrogen, melatonin, and other tests.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  17. Number of participants with Blood samples

    Venous blood samples were collected from all included patients at 5 mL per person.The obtained blood samples were placed at -8°C. Samples were immediately separated, partitioned and stored after collection, and some blood samples were immediately sent to the hospital for biochemical indexes.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

  18. Urine test

    Drink little or no water before going to bed, and try to retain urine in the bladder for more than 4 hours, use a sterile wide-mouth container to collect, discard the anterior part of the urine, and retain about 10mL of the middle part of the urine into a sterile container, and send it to the test immediately.

    Time frame: Pre-treatment, 3, 6, 9, 12 months post-treatment

07

Study locations

1 site
  • Prokin balance apparatus
    Hangzhou, Zhejiang 310006, China
    • Jingying Liang, master candidate · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Dec 2026, 27 months later.

Of 224 non-industry interventional studies with no phase under Scoliosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 58. This study's planned 27 months is above that.

Counting every sponsor, half of 234 studies reached it within 22 months; a quarter within 8 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2024
First posted
Jul 17, 2024
StartEst.
Sep 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06506227
Lead sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Responsible party
Sponsor
First posted
Jul 17, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 17, 2024

Study contacts

Jiang Zhong, bachelor
Contact
pjjzh@163.com
13588887567
Honggen Du, bachelor
Contact
duhonggen1212@163.com
13958088996
Jiang Zhong, bachelor
study director · The First Affiliated Hospital of Zhejiang Chinese Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion